3 Cases of Thrombotic Microangiopathy Induced by Low Dose Mitomycin-C / 대한신장학회잡지
Korean Journal of Nephrology
;
: 135-141, 2003.
Artículo
en Coreano
| WPRIM
| ID: wpr-12007
ABSTRACT
Mitomycin (MMC) is a naturally ocurring alkylating agent, introduced for clinical use as early as 1958. This drug is useful in the therapy of gastrointestinal carcinomas when used in combination with 5-fluorouracil. Nephrotoxicity among toxicities from MMC is unusual with cumulative doses less than 30 mg/m2. In large studies in which the incidence of MMC nephrotoxicity were assessed, 3-15% of patients developed total dose related renal dysfunction. Three patients in our clinical practice have developed thrombotic microangiopathy clearly related to MMC. We report the clinical and pathologic features of our cases. In view of the probable dose-related and delayed toxicity of MMC, it seems necessary to monitor regularly after initiation of chemotherapy. Early detection of the renal impairment and withdrawal of MMC might halt further progression of renal failure.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Incidencia
/
Mitomicina
/
Quimioterapia
/
Insuficiencia Renal
/
Microangiopatías Trombóticas
/
Fluorouracilo
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
/
Estudio de tamizaje
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Nephrology
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS